Eco Animal Health Group PLC AGM Statement (9258L)
16 Septiembre 2021 - 1:00AM
UK Regulatory
TIDMEAH
RNS Number : 9258L
Eco Animal Health Group PLC
16 September 2021
ECO Animal Health Group plc
("ECO" or "the Group")
AGM Trading Statement
The Board of ECO Animal Health Group plc (AIM: EAH) issues a
trading update ahead of its Annual General Meeting to be held later
today.
The Group reported an exceptional recovery from the African
Swine Fever outbreak in China during 2019 and 2020 to record
revenues in China and Japan which were 154% higher in the year
ended 31 March 2021 compared with the prior year. The Group's
outlook statement issued on 26 July 2021 in connection with the
publication of the Annual Report, indicated that Group revenue was
marginally behind the unprecedented prior year and the previous
strength seen in the China market had eased significantly following
the decline in pork prices. The outlook statement also indicated
that the Board expected the Group's historical pattern of second
half revenue weighting would be repeated in the current financial
year. This was specifically related to China where market softness
in the first quarter was expected to reverse later in the year as
state purchasing of pork would improve producer margins.
During the second quarter the easing of the Chinese market
continued and the revenue from China in the five months ended 31
August 2021 (the "Period"), representing 40% of total Group revenue
compared with 48% in the prior period, was significantly lower than
budget and the prior year. It is expected that there will be some
recovery in China revenues during the remainder of our financial
year due to:
-- Pork prices continuing to improve with state sponsored purchasing of pork
-- Increased Autumn and Winter pork consumption
-- Increased Autumn and Winter respiratory disease prevalence
leading to greater demand for Aivlosin(R)
-- A marketing and sales focus on both mid-tier and large
producers, supported by a series of national and regional technical
seminars
-- Sequential monthly revenue has increased for the last three months
Elsewhere, overall revenues in the Period have been behind a
budget which assumed no seasonality but ahead of the prior
year.
In aggregate, the impact of China resulted in Group revenue for
the five months ended 31 August 2021, being 6% lower than the
comparative period last year.
In the remainder of the financial year, recovery in the Chinese
market is expected to result in improved trading. The markets
across the rest of the world for the Group's products are expected
to remain firm and the Board looks forward cautiously but
positively to the rest of the year.
Marc Loomes, CEO, commented:
"The commodity price reduction seen in China since our year end
has put additional pressure on the pork production industry. Many
producers are trading at or below breakeven point, and this has
resulted in significant headwinds in our sales efforts. We expect
ongoing improvements in the prospects for sales in China, as the
current imbalance of supply and demand is rectified and the typical
seasonal increase in the demand for Aivlosin(R) in the winter
months develops. Notwithstanding the first half shortfall in China
we are encouraged with the revenue performance elsewhere in the
Group's international markets."
The information contained within this announcement is deemed by
the Group to constitute inside information as stipulated under the
Market Abuse Regulations (EU) No. 596/2014 ("MAR") as it forms part
of United Kingdom domestic law by virtue of the European Union
(Withdrawal) Act 2018. Upon the publication of this announcement
via a Regulatory Information Service ("RIS"), this inside
information is now considered to be in the public domain.
Contacts:
ECO Animal Health Group plc
Marc Loomes (CEO)
Chris Wilks (FD) 020 8447 8899
IFC Advisory
Graham Herring
Zach Cohen 020 3934 6630
Singer Capital Markets (Nominated Adviser
& Joint Broker)
Mark Taylor
George Tzimas
Sam Butcher 020 7496 3000
Peel Hunt LLP (Joint Broker)
James Steel
Dr Christopher Golden 020 7418 8900
About ECO Animal Health
ECO Animal Health Group plc ("ECO" or "the "GROUP") researches,
develops and commercialises products for livestock. Our business
strategy is to generate shareholder value by achieving the maximum
sales potential from the existing product portfolio whilst
investing in Research and Development ("R&D") for new products,
particularly vaccines, and seeking to in-license new products.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGMSFAFAIEFSESU
(END) Dow Jones Newswires
September 16, 2021 02:00 ET (06:00 GMT)
Eco Animal Health (LSE:EAH)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Eco Animal Health (LSE:EAH)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024